Kopran Limited (NSE:KOPRAN)
265.21
+5.45 (2.10%)
Nov 11, 2026, 1:30 PM IST
Kopran Revenue
Kopran had revenue of 2.12B INR in the quarter ending September 30, 2026, with 79.70% growth. This brings the company's total for the last twelve months to 7.94B, up 34.19% year-over-year. In the fiscal year ending March 31, 2026, Kopran had annual revenue of 6.81B with 8.23% growth.
Revenue (ttm)
7.94B
Revenue Growth
+34.19%
P/S Ratio
1.58
Revenue / Employee
6.87M
Employees
1,156
Market Cap
12.80B
Revenue by Geography
- India 2.28B 33.8%
- South Africa 1.26B 18.7%
- Rest of World 1.24B 18.4%
- Ethiopia 798.25M 11.8%
- Bangladesh 331.89M 4.9%
- United Kingdom 175.56M 2.6%
- Jordan 141.33M 2.1%
- Other 521.20M 7.7%
Fiscal year ended Mar 31, 2026 See the full Kopran breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 6.81B | 518.19M | 8.23% |
| Mar 31, 2025 | 6.30B | 150.13M | 2.44% |
| Mar 31, 2024 | 6.15B | 636.05M | 11.54% |
| Mar 31, 2023 | 5.51B | 734.66M | 15.38% |
| Mar 31, 2022 | 4.78B | -142.93M | -2.91% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Marksans Pharma | 33.92B |
| Pfizer | 26.54B |
| Rubicon Research | 21.00B |
| CORONA Remedies | 15.59B |
| Sanofi Consumer Healthcare India | 9.79B |
| SMS Pharmaceuticals | 9.74B |
| Senores Pharmaceuticals | 7.19B |
| Sai Parenteral's | 6.74B |